Lung cancer is the leading cause of cancer death in both men and women. Clinical staging
plays a crucial role in predicting survivor as well as influencing management option in lung …

Lung cancer is the leading cause of cancer-related mortality in the United States, and
accurate staging plays a vital role in determining prognosis and treatment. The recently …

The tumor, node, metastasis (TNM) staging system approved by International Association for
the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC) to …

Lung cancer is the first leading cause of cancer deaths worldwide. Non‐small cell lung
cancer (NSCLC) is the most common type of lung cancer. Increasing evidence shows that …

Lung cancer is the second-most commonly diagnosed cancer and the leading cause of
cancer death worldwide. The most common histological type is non-small-cell lung cancer …

Background The recent discovery of miRNAs and lncRNAs in urine exosomes has emerged
as promising diagnostic biomarkers for bladder cancer (BCa). However, mRNAs as the …

Background B and T lymphocyte attenuator (BTLA) is a novel immune checkpoint with an
unclear role in non–small-cell lung cancer (NSCLC). In contrast, the programmed death-1 …

Background Cancer recurrence after tumor resection in early-stage non-small cell lung
cancer (NSCLC) is common, yet difficult to predict. The lung microbiota and systemic …

The goal of clinical proteomics is to identify, quantify, and characterize proteins in body fluids
or tissue to assist diagnosis, prognosis, and treatment of patients. In this way, it is similar to …

Simple Summary Stage III non-small cell lung cancer (NSCLC) is a highly heterogeneous
group of diseases with wide differences in tumor size and in nodal involvement and …